Clinical Trials
52 trialsNCT05099848 2026-05-22
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Completed
NCT00959647 2026-05-08
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT03259035 2026-04-09
NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT02359968 2026-03-18
PROTECT
Centre Oscar Lambret
Phase 2 Completed
NCT03092895 2026-01-29
A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT05480306 2025-08-03
DeFianCe
Leap Therapeutics, Inc.
Phase 2 Completed
NCT03186326 2025-06-29
SAMCO
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT03584711 2025-06-29
OPTIPRIME
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT03861702 2025-04-18
Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT04380337 2025-02-25
Organ Preservation Program Using Short-Course Radiation & FOLFOXIRI in Rectal Cancer
Stanford University
Phase 2 Completed
NCT03662659 2025-02-05
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Bristol-Myers Squibb
Phase 2 Completed
NCT02000050 2025-01-30
COLORE
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Completed
NCT01274962 2024-06-26
A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Completed
NCT02243358 2023-10-27
Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Henry Ford Health System
Phase 2 Completed
NCT02017704 2023-10-17
CORRECT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01622543 2023-08-23
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT04217954 2023-06-23
HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
Peking University
Phase 2 Completed
NCT01516216 2022-04-26
Study of Vitamin D in Untreated Metastatic Colorectal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00591123 2021-10-01
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
Translational Oncology Research International
Phase 2 Completed
NCT00381706 2021-09-29
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT02845908 2021-04-23
POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC
Fujian Cancer Hospital
Phase 2 Completed
NCT00066274 2021-03-02
Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer
UNICANCER
Phase 2 Completed
NCT00006050 2021-02-17
Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
UNICANCER
Phase 2 Completed
NCT01417494 2020-11-03
1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT01363843 2020-06-11
Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
Brown University
Phase 2 Completed
NCT01498289 2019-11-07
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT02981498 2019-03-06
Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma
Sun Yat-sen University
Phase 2 Completed
NCT01283204 2019-01-29
Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer
Yonsei University
Phase 2 Completed
NCT00613080 2018-09-25
Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00551213 2018-08-24
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02195180 2018-07-27
Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma
ERYtech Pharma
Phase 2 Completed
NCT01288339 2018-05-16
PULSE
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Completed
NCT01418222 2017-05-30
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer
Genentech, Inc.
Phase 2 Completed
NCT01581307 2017-03-03
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03048123 2017-02-09
HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B
Sun Yat-sen University
Phase 2 Completed
NCT01749956 2017-02-07
5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01269229 2016-09-07
A Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis
Yonsei University
Phase 2 Completed
NCT00890305 2015-07-08
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
Medivation, Inc.
Phase 2 Completed
NCT00673673 2015-02-04
FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Yale University
Phase 2 Completed
NCT00016198 2013-06-26
Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00103298 2013-06-20
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025142 2013-05-15
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00615056 2013-04-19
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
Pfizer
Phase 2 Completed
NCT00202787 2013-02-20
Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Completed
NCT00004127 2013-02-11
Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach
University of Chicago
Phase 2 Completed
NCT00016978 2013-02-05
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan
National Cancer Institute (NCI)
Phase 2 Completed
NCT01605305 2012-05-24
Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer
Fudan University
Phase 2 Completed
NCT00786006 2011-12-06
Randomized Phase II Study of FOLFOX Versus FOLFIRI.3 in Gemcitabine-refractory Pancreatic Cancer
Asan Medical Center
Phase 2 Completed
NCT00866944 2011-11-11
MT201-204
Amgen Research (Munich) GmbH
Phase 2 Completed
NCT00004102 2011-03-28
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
NYU Langone Health
Phase 2 Completed